News for Soleno Therapeutics, Inc. (SLNO)

VYKAT XR launch generates $32M, addressing unmet Prader-Willi needs. Soleno (SLNO) stock fairly valued; potential buyout offers intriguing investment prospects. See more.

In recent stock market news, Soleno Therapeutics (SLNO) has caught the attention of investors following an update from Baird. Analyst Brian Skorney has reaffirm

Baird analyst Brian Skorney has increased the price target for Soleno Therapeutics (SLNO), raising it from $105 to $121. This adjustment follows the company's i

REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) ( SLNO), a biopharmaceutical company developing novel therapeutics

Soleno Therapeutics (SLNO) has announced the pricing of its underwritten public offering, releasing 2,352,941 shares of common stock at $85.00 each. The company

Soleno Therapeutics (SLNO) intends to raise approximately $200 million through a public offering of 2,352,941 shares at $85.00 per share. The proceeds w

Soleno Therapeutics (SLNO) aims to raise $200M via a public offering to fund VYKAT XR commercialization, EU regulatory efforts, R&D, and corporate needs.

REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) ( SLNO), a biopharmaceutical company developing novel therapeutics

REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (SLNO), a biopharmaceutical company developing novel therapeutics f

Soleno Therapeutics (SLNO) has revealed initial unaudited financial metrics for the second quarter ending June 30, 2025. The company anticipates net revenue fro

Soleno Therapeutics (SLNO) has announced its intention to raise $200 million through the sale of common stock in an underwritten public offering. Additionally,

REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the three months ended June 30, 2025:

REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. The proposed public offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

On June 25, 2025, COMMODORE CAPITAL LP (Trades, Portfolio) made a significant move by acquiring 1,175,000 shares of Cidara Therapeutics Inc (CDTX). This transac

REDWOOD CITY, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that two abstracts featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets, previously known as DCCR, have been selected for presentation at the Annual Meeting of the Endocrine Society (ENDO 2025), which is being held July 12-15, 2025, in San Francisco, CA.

Soleno Therapeutics (SLNO) recently caught the attention of TD Cowen analyst Tyler Van Buren, who initiated coverage with a Buy rating and set a price target of

Summary Soleno Therapeutics Inc (SLNO), a biopharmaceutical company focused on developing treatments for rare diseases, announced its participation in the 2025

Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and

On May 29, 2025, Carlyle Group Inc. (Trades, Portfolio) executed a significant transaction involving StandardAero Inc. The firm reduced its holdings in Standard